Introduction
============

Sphingosine-1-phosphate (S1P), initially considered as an intermediate breakdown product of complex sphingolipid catabolism, is meanwhile acknowledged as important bioactive lipid ([@B83]; [@B70]; [@B13]; [@B109]). S1P regulates crucial cellular functions such as proliferation and survival, migration, and adhesion ([@B83]; [@B13]). Systemic and local gradients of S1P provide direction for migration and trafficking of various cell types ([@B99]; [@B95]). Metabolically, S1P resides in a dynamically balanced equilibrium with sphingosine and ceramide ([@B43]; [@B94]). Ceramide, derived from *de novo* sphingolipid synthesis, from breakdown of glycosphingolipids or via the sphingomyelin cycle, can be converted reversibly into sphingosine, which in turn can be phosphorylated to S1P by the sphingosine kinases, SphK1 and SphK2 ([@B43]). S1P is a substrate of specific S1P phosphatases and non-specific lipid phosphate phosphatases which direct the equilibrium into the direction of sphingosine/ceramide ([@B43]). S1P can also be cleaved by S1P lyase, which generates hexadecenal and phosphoethanolamine and thus catalyzes an irreversible step of sphingolipid breakdown ([@B5]).

With regard to its complexity and to the multitude of options for pharmacological interventions, the S1P signaling system might well be compared to the adrenergic system. First of all, there are five specific G-protein-coupled S1P receptors, which are widely expressed and can act both in a redundant and in an antagonistic manner by coupling to distinct G-proteins ([@B13]; [@B64]), reminiscent of α~1~, α~2~, and β adrenergic receptors ([@B16]; [@B7]). Furthermore, the enzymes which catalyze the formation and degradation of S1P, as well as the specific and non-specific S1P transporters, represent promising drug targets ([@B88]; [@B102]; [@B95]), reminiscent of the enzymes of catecholamine synthesis and degradation as well as the catecholamine transporters ([@B8]). However, drug development targeting the S1P signaling system has focused almost exclusively on the S1P~1~ receptor until now ([@B112]; [@B12]; [@B38]). This is not least due to the success of the non-specific S1P receptor agonist, fingolimod, which has been approved for the treatment of multiple sclerosis in 2010/11 by the FDA and the EMA, respectively ([@B65]). In brief, phosphorylated fingolimod, acting as a superagonist or functional antagonist at S1P~1~, causes internalization and degradation of the receptor, thereby rendering lymphocytes insensitive to the tissue-blood S1P gradient with the consequence of lymphopenia ([@B12]). Subsequent to the approval of fingolimod, novel S1P~1~ functional or competitive antagonists with improved properties are presently being developed ([@B88]; [@B112]; [@B12]; [@B38]). While the development of sphingosine kinase and S1P lyase inhibitors has turned out to be not that straightforward (see e.g., [@B129]; [@B25], and discussion in [@B88]), the focus on G-protein-coupled S1P receptors other than S1P~1~ might be promising. Aside from causing immunosuppression, the effects of S1P~1~ receptor antagonism are rather undesirable: elevation of blood pressure, bronchial constriction, and on the long term a disturbance of the vascular endothelial barrier ([@B12]). Since the S1P~2~ receptor often acts contrarily to S1P~1~, S1P~2~ antagonists might turn up as promising tools for improving local blood flow in combination with tightening of the endothelial barrier, as anti-inflammatory and anti-fibrotic treatment options, and as potentially beneficial to treat the metabolic syndrome. The current review will discuss this therapeutic potential of S1P~2~ receptor antagonists and potential risks.

Overview of G-Protein-Coupled S1P Receptors and Specific Features of S1P~2~
===========================================================================

There are five specific G-protein-coupled receptors with a high affinity for S1P. According to the International Union of Basic and Clinical Pharmacology (IUPHAR) receptor nomenclature, they are named S1P~1~--S1P~5~ (human gene names S1PR1--S1PR5; [@B64]). S1P~1-3~ are expressed nearly ubiquitously, whereas S1P~4~ is preferentially expressed in the hematopoietic system, and S1P~5~ is found in the white matter of the brain as well as in some other tissues ([@B13]; [@B64], [@B65]; [@B110]). S1P~1~ couples exclusively to G~i~, while S1P~2~ and S1P~3~ couple to G~i~, G~q~, and G~12/13~. S1P~4~ and S1P~5~ couple to G~i~ and G~12/13~. These receptors regulate cell growth and survival, migration, and adhesion. Thereby they orchestrate for example the circulation of lymphocytes, the formation and maturation of blood vessels, vascular tone and permeability, as well as heart rate ([@B13]; [@B64]). Furthermore, they play a role in inflammation, fibrosis, and cancer ([@B83]; [@B131]; [@B94]; [@B110]).

The S1P~2~ receptor, also referred to as EDG-5, H218, AGR16, or lp~B2~, was originally cloned from rat aortic vascular smooth muscle cells ([@B98]) and later identified as high-affinity S1P receptor ([@B37]). With a *K*~d~ of 27 nM and an EC~50~ in GTPγS binding of 3.8--8.9 nM, the affinity of S1P to S1P~2~ appears marginally lower than its affinity to S1P~1~ (*K*~d~ of 8 nM and EC~50~ in GTPγS binding 0.4--79; for review, see [@B140]; [@B64]). S1P~2~ is coupled via G~i~, G~q~, and G~12/13~ to phospholipase C, \[Ca^2+^\]~i~ increases, activation of mitogen-activated protein kinases, and activation of Rho and/or Rho kinase (reviewed in [@B136]; [@B1]; [@B13]). Similar to S1P~1~, S1P~2~ can be internalized upon stimulation with agonists (see e.g., [@B148]; [@B53]). Mechanistically, this has been analyzed in zebrafish. The zebrafish miles apart mutant, S1P~2~ R150H, which impedes the migration of cardiac precursor cells to the midline, was shown to be constitutively desensitized and internalized ([@B15]). As this involved β-arrestin-2 and G-protein-coupled receptor kinase (GRK)-2, S1P~2~ R150H receptor functionality could be restored by reduced GRK2/3 expression ([@B15]).

S1P~2~ can activate Akt ([@B87]), but in most cells, it inhibits Akt ([@B130]; [@B30]; [@B89]; [@B40]; [@B56], and many other reports), and it can act pro- as well as anti-proliferative. Similarly, S1P~2~ can both activate and inhibit Rac ([@B97]; [@B144]; [@B146]; [@B111]). S1P~2~ inhibited the phosphatidylinositol-3-kinase/Akt pathway by mediating Rho-dependent activation of the phosphoinositide phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in fibroblasts and endothelial cells ([@B125], [@B124]), but in macrophages, S1P~2~-mediated inhibition of Akt and migration were independent of PTEN ([@B89]). Via G~12/13~ or G~q~ and activation of Rho/Rho kinase, in conjunction with inhibition of Rac, S1P~2~ exerts its eminent anti-migratory effect, important, e.g., for retention of B cells and follicular T helper cells in germinal centers ([@B40]; [@B92]). The S1P~2~ receptor can furthermore regulate cytoskeleton organization via phosphorylation of ezrin/radixin/moesin (ERM) proteins ([@B35]). This pathway appears to be involved in control of the endothelial barrier function and cancer cell invasion ([@B4]; [@B2]). Another signaling pathway recently discovered to be regulated by G-protein-coupled receptors including S1P~2~ is the Hippo pathway ([@B160]). S1P~2~, again via G~12/13~ and Rho, activated the transcription coactivators, YAP and TAZ ([@B90]; [@B160]). This occurred independently of the core Hippo pathway kinases ([@B90]), or via inhibition of LATS1/2 ([@B160]). The Hippo pathway regulates tissue proliferation and organ size, and plays a role in tumorigenesis ([@B162]; [@B157]).

The S1P~2~ receptor itself might be regulated by signals other than S1P. Thus, a recent report suggests that the well-known effect of S1P~2~ on neurite retraction ([@B86]; [@B149]) might be involved in neuronal Nogo-A signaling ([@B61]). It was shown that Nogo-A-Δ20 directly activated S1P~2~ by binding to its extracellular loops 2 and 3 independently of the presence of S1P, and via S1P~2~/G~13~/RhoA inhibited neurite outgrowth and repressed synaptic plasticity ([@B61]). The authors suggested that the S1P~2~ receptor is a multi-ligand receptor, regulated by both lipid and protein ligands ([@B61]). Yet other potential agonists at S1P~2~ might be conjugated bile acids such as taurocholate ([@B143]). Several reports show that effects of conjugated bile acids, such as activation of ERK and Akt in primary rodent hepatocytes, and cell growth, survival, induction of cyclooxygenase (COX)-2 and formation of prostaglandin (PG)E~2~ in cholangiocarcinoma cells, are dependent on the S1P~2~ receptor, as they are blocked by the antagonist JTE-013 and by knocking down S1P~2~ ([@B143]; [@B79], [@B78]). While these observations do not preclude that preparations of conjugated bile acids contain traces of S1P, taurocholate specifically induced ERK phosphorylation in S1P~2~ but not S1P~1~ overexpressing HEK-293 cells (data obtained with the other S1P receptors were not shown; [@B143]), thereby rebutting the contamination hypothesis. A direct interaction is furthermore supported by molecular modeling of taurocholate into S1P~2~ ([@B143]).

S1P~2~ Receptor Pharmacology
============================

S1P~2~ receptor pharmacology is still in its infancy as only few S1P~2~ selective compounds have been identified so far. These are still experimental tool compounds. Until recently, JTE-013 ([@B103]) was the only available S1P~2~ antagonist. Many functional studies have made use of this compound and thus, besides the results obtained with genetic approaches, the effects of JTE-013 have shaped our present view of the physiological roles of S1P~2~. However, JTE-013 has a low potency and lacks selectivity. This is illustrated by the fact that JTE-013 inhibited responses to S1P in S1P~2~ knockout mice, and it had effects in cells that had no S1P~2~ mRNA transcripts ([@B122]; [@B75]). Later, it was found that JTE-013 inhibited not only S1P~2~ but also the S1P~4~ receptor ([@B80]). Furthermore, JTE-013 lacks stability *in vivo* ([@B77]). Recently, AB1 has been developed as derivative of JTE-013 with improved stability *in vivo*, higher potency and better efficacy, but the selectivity of the compound is not well defined so far ([@B77]). Other recently synthesized S1P~2~ antagonists require further characterization ([@B71]). Interestingly, a series of S1P~2~ agonists has also been described, of which at least CYM-5520 acted at an allosteric site ([@B127]). While not much is known so far concerning the biological effects of CYM-5520, the related compound CYM-5478 ([@B127]) reduced cisplatin-mediated cell death by reducing reactive oxygen species (ROS) in C6 glioma cells ([@B45]). Taken together, further development is required in the area of S1P~2~ receptor pharmacology.

Anti-Migratory Effect of S1P~2~ and Consequences for Angiogenesis and B Cell Homing
===================================================================================

One of the main effects of the S1P~1~ receptor is induction of migration and chemotaxis within gradients of S1P ([@B141]). In contrast to S1P~1~, S1P~2~ inhibits migration in many cell types, including vascular endothelial and smooth muscle cells as well as tumor cells, via activation of Rho and inhibition of Rac ([@B97]; [@B9]; [@B39]; [@B73]; [@B147]; [@B146]). The S1P~2~ antagonist JTE-013 augmented S1P-induced angiogenesis *in vivo* in a Matrigel implant assay ([@B54]). The S1P~2~ receptor appears to be upregulated in senescent endothelial cells, such as pulmonary microvascular endothelial cells from aged rats, and senescence-associated impairment in chemotaxis and migration was attenuated by down-regulation of S1P~2~ ([@B82]). In human umbilical vein endothelial cells, the S1P~2~ receptor suppressed angiogenic sprouting via a Gα~12/13~/leukemia-associated RhoGEF (LARG)/RhoC-signaling cascade ([@B24]). Nevertheless, both pro- and anti-migratory S1P receptors, i.e., S1P~1-3~, are required for proper development of the vasculature during embryonic development ([@B68]). In the mouse retina, S1P~2~ was not required for normal angiogenesis ([@B138]). Interestingly, S1P~2~ was induced by hypoxia, and its knockout reduced the hypoxia-associated pathologic neovascularization in the vitreous chamber, while it augmented the revascularization into the avascular zones of the retina ([@B138]). While these observations suggest that antagonism at S1P~2~ might be useful for treatment of pathologic neovascularization, S1P~2~ knockout in fact went along with enhanced tumor angiogenesis ([@B30]), suggesting that this indication should be regarded with caution.

Interestingly, similar to the pro-migratory effect of the S1P~1~ receptor, which is required for lymphocyte egress from secondary lymphatic tissues, the anti-migratory effect of the S1P~2~ receptor plays an eminent role in the regulation of lymphocyte localization. By inhibition of migration and proliferation, S1P~2~ mediates the confinement of B cells and follicular T helper cells to lymph node germinal centers ([@B40]; [@B92]). It is likely a consequence thereof that mice lacking the S1P~2~ receptor develop clonal B cell lymphomas with age ([@B18]). Furthermore, somatic mutations in the 5′ sequence of the S1PR2 gene were detected in about 25% of human germinal center-derived diffuse large B cell lymphomas ([@B18]). Importantly, mice which were heterozygous for the S1P~2~ receptor did not develop lymphomas ([@B18]), suggesting that treatment with a pharmacological inhibitor would probably not cause this devastating condition, although this is clearly one of the critical facets in S1P~2~ antagonist development.

Contractile Effect of S1P~2~ in Smooth Muscle and Consequences for Vessel Tone, Blood Flow, and Inner Ear Function
==================================================================================================================

The S1P~2~ receptor induces contraction of diverse types of smooth muscle, including vascular, bronchial, intestinal, and bladder smooth muscle, by inducing increases in intracellular Ca^2+^ concentration and activation of Rho/Rho kinase ([@B96]; [@B48]; [@B62]). In the vascular system, endothelial S1P~1~ and S1P~3~ receptors mediate NO-dependent vasodilation, while smooth muscle S1P~2~ and S1P~3~ receptors mediate vasoconstriction, with differential responses in different vascular beds ([@B49]; [@B63]). S1P~2~ knockout mice had normal mean arterial pressure and left ventricular function, but reduced renal and mesenteric vascular resistance which went along with an enhanced blood flow in the affected areas ([@B81]). Furthermore, the S1P~2~ receptor contributed to blood pressure elevation and vasoconstriction after α-adrenergic stimulation ([@B81]). In a mouse model of myocardial infarction-induced heart failure, S1P~2~ knockout mice did not develop enhanced myogenic responses ([@B46]). While blood flow in cerebral arteries was dependent on S1P~3~ ([@B122]), S1P~2~ appears to play a role in perfusion of lung, liver, and kidney. Thus, S1P~2~ activation increases pulmonary vascular resistance in isolated perfused mouse lung ([@B145]). Another study suggested that S1P-induced pulmonary vasoconstriction was mediated by S1P~4~ ([@B107]), but it is a contradiction that JTE-013, as a S1P~2~/S1P~4~ antagonist ([@B80]), had no effect in that study. Interestingly, hypoxia-induced pulmonary hypertension in rodents was reduced by JTE-013 ([@B19]). In agreement, S1P~2~ antagonists have been suggested for the treatment of pulmonary hypertension ([@B154]). In isolated perfused rat liver, S1P~2~ activation increased portal pressure ([@B50]), and S1P~2~ antagonism reduced portal vein pressure in cirrhotic rats after bile duct ligation ([@B59]). Finally, S1P~2~-mediated vasoconstriction in the isolated perfused kidney was enhanced in diabetic rats ([@B10]).

While these results suggest that S1P~2~ antagonism could be helpful to increase organ blood flow, there is also a caveat: S1P~2~ knockout mice are deaf and have a progressive loss of vestibular function ([@B84]). Among the earliest lesions in the cochlea of S1P~2~-deficient mice, there were defects in the stria vascularis ([@B67]). These data suggest that the absence of S1P~2~ caused a dysregulation of the spiral modiolar artery tone, and subsequently an abnormal perfusion of the inner ear, which is accountable for the phenotype ([@B67]). In addition, the S1P~2~ receptor also contributes to cochlear hair cell maintenance and survival ([@B44], [@B45]). Thus, it was shown recently that ROS accumulated in the cochlea of S1P~2~ knockout mice ([@B45]). Furthermore, S1P~2~ inhibited NADPH oxidase-3 activity in a recombinant system, and the S1P~2~ agonist, CYM-5478, reduced cisplatin-induced ROS formation in C6 glioma cells ([@B45]). Also very recently, the S1P~2~ receptor gene has been allocated to the autosomal-recessive non-syndromic hearing impairment locus DFNB68 on chromosome 19, and two pathogenic S1P~2~ variants have been identified ([@B126]). In conclusion, S1P~2~ receptor agonists might be a treatment option for cisplatin- or gentamicin-induced ototoxicity ([@B93]; [@B45]), while S1P~2~ antagonists will have to be analyzed for potential ototoxic effects.

Vascular Permeability and Vascular Inflammation
===============================================

While early studies reported that functional antagonists at S1P~1~ improved the vascular endothelial barrier, e.g., in lipopolysaccharide (LPS)-induced edema, it soon turned out that this was due to the initial agonistic activity of the compounds, which was however followed by an increase in vascular permeability on the long term ([@B155]). Here again, the S1P~2~ receptor plays an opposite role, as activation of S1P~2~ causes a disruption of endothelial adherens junctions and increased paracellular permeability. Consequently, JTE-013 improved barrier integrity ([@B124]). An improvement of the vascular barrier by knockout or inhibition of S1P~2~ has been shown in endothelial cell cultures and in diverse *in vivo* models including stroke ([@B66]), experimental autoimmune encephalitis (EAE; [@B21]), and anaphylactic shock (see below). Thus, JTE-013 attenuated the H~2~O~2~-evoked vascular leak in the isolated perfused rat lung ([@B124]). LPS and tumor necrosis factor-α (TNF-α) upregulated S1P~2~ in endothelial cells. Importantly, vascular inflammation induced by LPS or TNF-α, with NF-κB activation and upregulation of vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, E-selectin, and monocyte chemoattractant protein (MCP)-1, was reduced by inhibition and/or knockout of S1P~2~ ([@B29]; [@B163]). In models of LPS-induced acute lung injury or endotoxemia, both vascular and alveolar leakage were reduced by these pharmacological or genetic approaches ([@B123]; [@B161]). Taken together, a barrier disruptive role of the S1P~2~ receptor, and thus a therapeutic potential for S1P~2~ antagonists in diverse conditions of vascular barrier breakdown, is supported by a broad range of studies. However, it was also shown that S1P~2~ might be protective against acute vascular barrier disruption in active anaphylaxis and after injection of platelet-activating factor ([@B22]; see below). These authors observed that the activities of Akt and endothelial NO synthase were enhanced in S1P~2~ knockout aorta, lung, and endothelial cells, and the enhanced NO release in turn compromised vascular barrier function ([@B22]). Furthermore, S1P~2~ contributed to maintenance of adherens junctions in this study, in contrast to previous reports ([@B124]). The reason for this, however, remains unclear.

Atherosclerosis
===============

S1P occurs at high concentrations in blood plasma and serum, where it is bound mostly to high-density lipoproteins and albumin, and both pro- and anti-atherosclerotic activities of S1P have been described ([@B74]). The S1P~2~ receptor, in particular, is significantly upregulated by inflammatory mediators in the endothelium, and it mediates vascular inflammation (see above), which might be a key factor for promoting atherosclerosis. In fact, S1P~2~ is upregulated in atherosclerotic endothelium ([@B31]). However, after carotid artery ligation, S1P~2~-deficient mice developed large neointimal lesions, which went along with medial and intimal smooth muscle proliferation ([@B134]), suggesting that S1P~2~ on vascular smooth muscle cells was atheroprotective. In agreement, S1P~2~, by inducing serum response-factor enrichment of CArG box promotor regions, induced phenotypic modulation of smooth muscle cells in response to S1P ([@B152]). On the other hand, atherosclerosis in the mouse aorta was decreased by S1P~2~ knockout in apolipoprotein E-deficient mice ([@B137]). This study showed that body weight, plasma cholesterol, plasma triglyceride, and lipoprotein profiles were not altered in atherosclerotic S1P~2~ knockout mice, but that the number of macrophages and foam cells infiltrating the vessel wall was decreased, and that S1P~2~ in the myeloid cells was responsible for the effect. It was concluded that S1P~2~ signaling retained macrophages in the plaques, where they promoted inflammation ([@B137]). Recently, it was shown that a knockout of both Gα~12~ and Gα~13~ in myeloid cells protected LDL receptor-deficient mice from atherosclerosis, which is of importance here, since the S1P~2~ receptor was identified as the major G~12/13~ activator in the relevant cells, which were identified as peritoneal macrophages ([@B41]). In brief, the authors showed that the alternative, anti-inflammatory polarization of aortic macrophages in those mice was an indirect effect, mediated by activation of atheroprotective B cells through classical, pro-inflammatory peritoneal macrophages. Importantly, in both bone marrow-derived and peritoneal macrophages from myeloid G~12/13~ knockout mice, pro-inflammatory cytokines were strongly upregulated, and this was mimicked by JTE-013 in wild-type macrophages ([@B41]). Thus, the study suggested that G~12/13~, and S1P~2~ as major G~12/13~ activator in macrophages, decreased rather than increased pro-inflammatory cytokine production, but nevertheless, atherosclerosis was attenuated by inhibition of this pathway ([@B41]). Taken together, inhibition of S1P~2~ might be atheroprotective, but further studies on the underlying mechanisms are clearly required.

Mast Cells and Anaphylaxis
==========================

Early reports have shown that in mast cells, the S1P~2~ receptor is involved in an autocrine loop that augments degranulation induced by Fc𝜀 receptor-I crosslinking ([@B58]). However, recent studies on the role of S1P~2~ in anaphylaxis yielded contradictory results (**Table [1](#T1){ref-type="table"}**): One group observed that JTE-013 and S1P~2~ knockout attenuated the severity of anaphylaxis and reduced circulating histamine levels as well as pulmonary edema and allergic lung infiltration in a mouse model of immunoglobulin E (IgE)/antigen-triggered anaphylaxis ([@B105], [@B104]). Interestingly, after histamine injection to shortcut mast cell degranulation, JTE-013 and S1P~2~ knockout did not attenuate the anaphylactic response, suggesting that S1P~2~ acted primarily by augmenting histamine release from mast cells during the onset of anaphylaxis ([@B105]). Another group observed that the symptoms of histamine-induced anaphylaxis were more severe in S1P~2~ knockout mice ([@B101]). Most importantly, they observed a poor recovery after both histamine and IgE/antigen challenge in these mice, which went along with a severe hypotension and a delay in plasma histamine clearance ([@B101], [@B100]). Yet another group even questioned that S1P~2~ knockout improved the vascular barrier breakdown, as deletion of this receptor aggravated the vascular leak and strongly impaired survival in mice challenged with antigen or platelet-activating factor ([@B22]). As possible explanations for the discrepant findings, differential responses of mast cell populations, the respective activity of the IgE preparations, active versus passive anaphylaxis as well as a role of the mouse strains were considered ([@B22]; [@B100]; [@B104]). Taken together, it remains open whether the potential beneficial effects of S1P~2~ antagonists, i.e., inhibition of mast cell degranulation, improvement of the vascular barrier, and attenuation of airway constriction, would outweigh their potential deleterious effect, i.e., aggravation of hypotension, in human anaphylaxis.

###### 

Overview of controversial publications on the role of the S1P~2~ receptor in anaphylaxis, inflammation and cancer.

  Anaphylaxis        Aggravation of anaphylaxis by S1P~2~        Attenuation of anaphylaxis by S1P~2~   Comments
  ------------------ ------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------
                     [@B58]                                                                             S1P~2~ augments degranulation by Fc𝜀 receptor-I.
                     [@B105], [@B104]                                                                   S1P~2~-KO and JTE-013 reduce histamine release and attenuate severity of anaphylaxis.
                                                                 [@B101], [@B100]                       Severe hypotension and delayed plasma histamine clearance in S1P~2~-KO.
                                                                 [@B22]                                 Impaired survival in S1P~2~-KO mice challenged with antigen; only study to show vascular leak in S1P~2~-KO.
                                                                                                        
  **Inflammation**   **Pro-inflammatory role of S1P~2~**         **Anti-inflammatory role of S1P~2~**   **Comments**
                                                                                                        
                     [@B135]; [@B14]; [@B106]                                                           S1P~2~ activates NF-κB.
                     [@B23]; [@B76]; [@B151]                                                            S1P~2~ induces COX-2 expression and PG synthesis.
                     [@B137]                                                                            S1P~2~-KO and JTE-013 reduce cytokine levels in LPS-treated mice.
                                                                 [@B142]                                S1P~2~ counteracts IL-1β in chondrocytes and cartilage.
                     [@B123]                                                                            S1P~2~-KO reduces bronchial leakage in LPS-induced lung injury.
                     [@B116]; [@B150]; [@B34]                                                           These studies show a principle role for S1P~2~ in allergic airway inflammation and constriction.
                     [@B20]                                                                             S1P~2~ is downregulated during sensitization, resulting in a loss of bronchoconstriction by S1P.
                                                                 [@B89]                                 S1P~2~-KO increases number of peritoneal macrophages in thioglycollate-induced peritonitis.
                     [@B114]                                                                            JTE-013 reduces cell recruitment after subcutaneous injection of zymosan.
                                                                                                        
  **Cancer**         **Pro-cancerous role of S1P~2~**            **Anti-cancerous role of S1P~2~**      **Comments**
                                                                                                        
                                                                 [@B18]                                 B cell lymphoma in homozygous S1P~2~-KO mice.
                                                                 [@B156]                                S1P~2~ overexpression and i.p. application of S1P reduce lung metastasis of implanted B16 melanoma cells.
                                                                 [@B30]                                 Accelerated tumor growth in S1P~2~-KO mice.
                     [@B159]; [@B121]; [@B108]; [@B60]; [@B11]                                          Role for S1P~2~ in metastasis and/or chemoresistance of diverse tumors and/or tumor cell lines
                     [@B90]; [@B160]; [@B2]                                                             Activation of pro-cancerous signaling pathways by S1P~2~
                     [@B77]                                                                             Anti-tumor effect of an S1P~2~ antagonist

KO, knockout. This table does not claim to be exhaustive.

Inflammation and Fibrosis
=========================

As mentioned above, the S1P~2~ receptor plays a role in vascular permeability and inflammation, atherosclerosis, mast cell function, and anaphylaxis. Further studies suggest that the S1P~2~ receptor acts pro-inflammatory also in other inflammatory settings. In LPS-treated mice, elevated serum levels of interleukin (IL)-1β and IL-18 were reduced by S1P~2~ knockout and JTE-013 ([@B137]). In diverse cell types, S1P~2~ activated NF-κB ([@B135]; [@B14]; [@B106]) or induced COX-2 expression and PG synthesis ([@B23]; [@B76]; [@B151]). As mentioned above, in a mouse model of LPS-induced lung injury, knockout of S1P~2~ reduced protein leakage into the bronchoalveolar lavage fluid ([@B123]). On the other hand, in primary human chondrocytes and osteoarthritis cartilage, S1P~2~ counteracted the pro-inflammatory signaling of IL-1β, including IL-1β-induced upregulation of inducible NO synthase ([@B142]).

S1P generally induces airway smooth muscle contraction ([@B113]) and plays a role in airway hyper-responsiveness and asthma ([@B69]; [@B115], [@B117]). Recently, it was shown that S1P repressed β~2~ adrenergic activity in airway smooth muscle cells by increasing COX-2-mediated PGE~2~ production ([@B118]). S1P~2~ and S1P~3~ appear to be involved in these effects (for review, see [@B72]). Thus, JTE-013 inhibited ovalbumin-induced contraction of lung parenchymal strips from ovalbumin-sensitized rats ([@B150]). However, in isolated bronchial rings, S1P augmented KCl-induced contraction in a JTE-013-sensitive manner only in bronchi from control mice, not from antigen-challenged mice, which was traced back to a down-regulation of S1P~2~ during sensitization ([@B20]). In contrast, S1P~2~ and S1P~3~ were upregulated during ovalbumin-sensitization in the study of [@B116]. Importantly, S1P~2~ and S1P~3~ receptors induced a steroid-resistant pro-remodeling response in airway smooth muscle cells ([@B34]). S1P~2~ furthermore had a pro-inflammatory influence on the bronchial epithelium, as S1P-induced IL-8 release via NF-κB was inhibited by JTE-013 in human bronchial epithelial cells ([@B106]). The data suggest that S1P~2~ antagonists might have a beneficial effect on airway inflammation and remodeling in asthma.

Notably, the inhibitory influence of S1P~2~ on migration plays an important role in the recruitment of inflammatory cells to sites of inflammation. Thus, in thioglycollate-induced peritonitis, knockout of the S1P~2~ receptor led to an increase in the number of macrophages in the peritoneal cavity ([@B89]). On the other hand, cell recruitment after subcutaneous injection of zymosan was reduced by JTE-013 ([@B114]). These seemingly contradictory observations suggest that the underlying migratory events of the different cell types are regulated in a complex manner by S1P~2~.

Some additional activities of the S1P~2~ receptor might be important in inflammation. Thus, S1P~2~ reduced antigen capture by murine Langerhans cells, thereby potentially alleviating cutaneous contact hypersensitivity ([@B55]). S1P~2~ furthermore suppressed macrophage phagocytosis, thereby impairing host defense in sepsis ([@B47]). Finally, while knockout and blockade of S1P~2~ improved the tightness of blood--brain barrier and ameliorated EAE, the receptor was found to be more abundant in female EAE mice and female patients with multiple sclerosis compared to their male counterparts, and it was suggested that this underlies the enhanced female CNS autoimmune susceptibility ([@B21]). Taken together, we are just beginning to understand the complex role of S1P~2~ in infection, inflammation, and autoimmunity.

With regard to fibrosis, it has been shown that intracellular S1P acts anti-fibrotic, while extracellular S1P has a pro-fibrotic activity. However, the respective role of the different S1P receptor subtypes appears to be less clear ([@B131]). In bleomycin-induced lung injury, a prolonged exposure to S1P~1~ functional antagonists including fingolimod not only worsened the vascular barrier function but also increased the fibrotic response ([@B133]), suggesting that S1P~1~ acts anti-fibrotic in pulmonary fibrosis. On the contrary, pro-fibrotic events such as Smad activation, induction of connective tissue growth factor (CTGF), and enhanced synthesis of extracellular matrix components, were dependent on signaling pathways involving G~12/13~ and/or Rho/Rho kinase, thereby pointing toward S1P~2~ and S1P~3~ as the main pro-fibrotic S1P receptors ([@B131]). Indeed, in carbon tetrachloride-induced liver fibrosis, S1P~2~ knockout mice showed reduced accumulation of hepatic myofibroblasts and decreased induction of fibrotic markers ([@B132]; [@B51]). Considering also the role of S1P~2~ in portal hypertension ([@B59]; see above), S1P~2~ antagonists may turn out to be helpful in liver fibrosis. Other reports suggest a role for S1P~2~ and/or S1P~3~ in pulmonary, renal, or cardiac fibrosis ([@B131]). Of note, also the S1P~5~ receptor appears to be involved in fibrosis, as it has recently been shown to induce CTGF expression in renal mesangial cells ([@B153]).

Diabetes Mellitus and Insulin Resistance
========================================

Function and survival of pancreatic β-cells, as well as the responsiveness of insulin-sensitive tissues to insulin, play an important role in diabetes mellitus, and both are regulated by the SphK/S1P axis ([@B57]; [@B33]). While earlier work showed that S1P itself contributed to glucose-stimulated insulin secretion and generally improved β-cell survival ([@B33]), it was shown recently that the S1P~2~ receptor had a rather negative impact on pancreatic β-cells. In streptozotocin-induced diabetes mellitus, S1P~2~ knockout mice had lower blood glucose levels, higher insulin/glucose ratios, less β-cell apoptosis, and a better survival rate ([@B52]). Furthermore, JTE-013 attenuated the development of diabetes in streptozotocin-treated wild type mice ([@B52]). In New Zealand obese mice, plasma concentrations of S1P increased over 28 days of high-fat diet, and treatment with JTE-013 reduced the concomitant β-cell loss ([@B56]). Mechanistically, S1P~2~ counteracted the anti-apoptotic and proliferative effects of insulin by inhibiting Akt ([@B56]).

Of the insulin-sensitive tissues, both skeletal muscle and hepatocytes were regulated by S1P~2~ ([@B111]; [@B32]). In C2C12 myoblasts, S1P caused a ROS-dependent transphosphorylation of the insulin receptor, thereby increasing glucose uptake into the cells. S1P-induced ROS production was inhibited by JTE-013, suggesting that it was the S1P~2~ receptor which mimicked the activity of insulin in myoblasts ([@B111]). In hepatocytes, however, S1P induced insulin resistance as it attenuated insulin-stimulated Akt phosphorylation in primary rat and human hepatocytes. This effect was sensitive to JTE-013, indicating an involvement of S1P~2~ which was the prevailing S1P receptor subtype on the mRNA level in hepatocytes. Importantly, in New Zealand obese mice, JTE-013 attenuated the continuous increase in blood glucose levels under high-fat diet, and partially reversed the high-fat diet-mediated loss in phospho-Akt in the liver of these mice ([@B32]). Thus, insulin sensitivity was regulated by S1P~2~ in a different manner in skeletal muscle and hepatocytes, respectively. Finally, it has to be mentioned that not much is known about S1P~2~ receptor activity in adipocytes, but a recent study suggests that the receptor had an anti-adipogenic effect in 3T3-L1 preadipocytes, as it decreased the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ), CCAAT/enhancer binding protein-α and adiponectin, and decreased the triglyceride content of the cells ([@B91]). Consequently, the authors concluded that activation of S1P~2~ might be helpful against obesity ([@B91]). However, one has to keep in mind, that activation of PPAR-γ is well-known to improve insulin sensitivity and plasma lipid profiles, and to inhibit inflammation ([@B158]; [@B17]). Thiazolidinediones, which are PPAR-γ agonists, have been used for years as insulin sensitizers in diabetes mellitus type 2, but they have been gradually removed from the market because of hepatotoxicity, increased cardiovascular risk, or increased occurrence of bladder cancer ([@B158]; [@B17]). Presently, pharmacologists aim at next-generation PPAR-γ agonists with improved safety profiles ([@B128]). In this context, it will be interesting to study the potential of S1P~2~ antagonists as inducers of PPAR-γ in relation to the reported negative effects of thiazolidinediones.

Skeletal Muscle
===============

The SphK/S1P axis plays an important role in skeletal muscle (patho)physiology, and the S1P~2~ receptor, in particular, is involved in myogenic differentiation and muscle regeneration ([@B26]). Thus, by antisense, silencing or overexpression approaches, it was shown that S1P~2~ induced differentiation of C2C12 myoblasts and contributed to myogenesis by low doses of TNF-α ([@B27], [@B28]). Importantly, S1P~2~ knockout mice had no alteration in the soleus muscle mass and morphology, however, as their body weight increased during aging stronger than that of wild-type mice, their muscle/body weight ratio decreased more strongly ([@B36]). In a model of soleus muscle degeneration by the myotoxic compound notexin, knockout of or antagonism at S1P~2~ delayed muscle regeneration and decreased the expression of the promyogenic marker myogenin ([@B36]). It was finally shown that S1P~2~ activated quiescent satellite cells and facilitated muscle regeneration via STAT3 (signal transducer and activator of transcription-3; [@B119]). Taken together, it will be important to analyze the impact of a long-term treatment with an S1P~2~ antagonist on skeletal muscle homeostasis.

Cancer
======

It appears obvious that inhibition of a receptor which acts anti-migratory and often anti-proliferative would result in enhanced tumorigenesis and particularly in metastasis. Indeed, lack or mutation of S1P~2~ is linked to B cell lymphoma, as explained above ([@B18]). In an early study with B16 melanoma cells which endogenously express only S1P~2~, pretreatment of the cells with S1P before implantation as well as daily i.p. application of S1P reduced lung metastasis, and stable overexpression of S1P~2~ enhanced this effect ([@B156]). Remarkably, this study not only shows an anti-metastatic role of S1P~2~, but also contradicts the anti-tumor effect of anti-S1P-antibody treatment reported in many studies (e.g., [@B3], for review see [@B120]). Furthermore, lung carcinoma and melanoma cells implanted into S1P~2~ knockout mice showed accelerated tumor growth, enhanced angiogenesis and more efficient recruitment of CD11b-positive bone marrow-derived cells into the tumors ([@B30]). However, several reports underline a rather pro-cancerous role of S1P~2~ (**Table [1](#T1){ref-type="table"}**): although S1P~2~ inhibited migration of glioma cells, it enhanced the expression of the matricellular protein CCN1/Cyr61 and stimulated glioma cell invasiveness and adhesion ([@B159]). In chronic myeloid leukemia, S1P~2~ enhanced Bcr--Abl1 stability via inhibition of protein phosphatase-2a, and inhibition of SphK1/S1P~2~ restored the chemosensitivity of leukemia allografts in mice ([@B121]). S1P~2~ also increased the chemoresistance of colon carcinoma cells ([@B60]). Inhibition of S1P~2~ upregulated breast carcinoma metastasis suppressor-1, which in turn suppressed lung metastasis of bladder carcinoma cells ([@B108]). Furthermore, pancreatic cancer cells implanted together with S1P~2~ receptor-deficient pancreatic stellate cells showed less cancer growth and metastasis *in vivo* ([@B11]). Moreover, the above-mentioned phosphorylation of ERM proteins mediated by S1P~2~ was suggested to take part in cancer cell invasion ([@B2]). Finally, S1P~2~-mediated activation of the Hippo pathway might be pro-cancerous ([@B90]; [@B160]; see above). As metastasis of epithelium-derived tumors has been linked to basal rather than apical epithelial extrusion, it is interesting to note that the S1P~2~ antagonist, JTE-013, preferentially inhibited apical extrusion ([@B42]), although the proposed role of reduced S1P production in basal extrusion of oncogenic K-Ras-expressing cells remains unclear as S1P production by these cells has not been quantified ([@B139]). Taken together, apart from the specific situation with S1P~2~ in B-cell lymphoma, the presently available studies suggest that the S1P~2~ receptor controls mechanisms which both promote and prevent tumor growth, invasion, and metastasis. Therefore, for development of S1P~2~ antagonists, thorough studies with the development candidates are required to address their potential for promotion of tumor growth and metastasis.

Conclusion
==========

As described in the present review, the S1P~2~ receptor plays an important role in many tissues and organs, and therefore, a therapeutic application of S1P~2~ antagonists will necessarily cause unintended effects. Here, an attempt is made to suggest potential therapeutic indications for S1P~2~ antagonists, and to point out the potential risks that have to be taken into account during drug development. First of all, the available data suggest that selective S1P~2~ receptor antagonists might be helpful in pulmonary hypertension, chronic obstructive pulmonary disease, and lung fibrosis. Similarly, portal hypertension and liver fibrosis, which often occur in conjunction, might be an indication. Although S1P~2~ antagonists will probably improve the vascular endothelial barrier, they are likely to cause problems in conditions with critical systemic arterial hypotension, such as sepsis or anaphylaxis. Finally, an interesting approach will be to test the therapeutic potential of S1P~2~ antagonists in diabetes mellitus type 2 with insulin resistance and progressive β-cell loss, and to see whether atherosclerosis is also attenuated in these patients. As the proposed indications require a chronic treatment, the potential long-term adverse effects need to be carefully addressed. Potentially devastating effects in the central nervous system, such as neuronal hyperexcitability, seizures, memory deficits, and increased anxiety ([@B85]; [@B6]), suggested by observations with S1P~2~ knockout mice or JTE-013 treatment, must be avoided by appropriate chemical--pharmaceutical engineering, i.e., by designing compounds that do not cross the blood brain barrier. Other critical points are inner ear functionality and B cell lymphoma. However, a full receptor knockout cannot be compared to the activity that can be reached with a (competitive) receptor antagonist. In this regard, it is important that mice that were heterozygous for the S1P~2~ receptor did not develop B cell lymphoma, and that hearing impairment due to S1P~2~ missense mutations in humans was autosomal-recessive. While the potential of S1P~2~ antagonists to induce or exacerbate tumor growth and metastasis has to be addressed carefully, these agents might also act protective in cancer. For instance, in a recent study with a novel S1P~2~ antagonist, which is a derivative of JTE-013 with improved properties, the compound inhibited the growth of neuroblastoma xenografts ([@B77]).

Indeed, a major problem in this research area is the lack of appropriate tools. As discussed above, the widely used S1P~2~ antagonist, JTE-013 ([@B103]), has a low potency and lacks selectivity and stability *in vivo* ([@B80]; [@B77]). Other more recently synthesized S1P~2~ agonists and antagonists still await further characterization ([@B127]; [@B71]; [@B77]). In conclusion, the discovery of novel highly selective antagonists with high affinity at S1P~2~ is urgently required to address pending questions regarding the roles and effects of S1P~2~, and to enable definite conclusions with regard to the therapeutic suitability of these drugs.
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